Keywords: Licensing, Debiopharm, Novartis, Teva, Active Biotech, Qiagen, Merck & Co, AnaptaysBio, Novavax, ROVI

Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped

Article | 09 February 2010

Switzerland’s Debiopharm Group has granted an exclusive, worldwide (excluding Japan) licence to Swiss drug major Novartis for the development, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in